HeartBeam Inc. (NASDAQ: BEAT) has strengthened its position in cardiac monitoring technology with the recent acquisition of two new U.S. patents, significantly enhancing its intellectual property portfolio. The company, focused on delivering personalized heart health insights through its 3D ECG platform, now holds more than 20 U.S. and international patents, with additional applications pending.
Robert Eno, CEO of HeartBeam, emphasized the company's vision to facilitate easier cardiac symptom monitoring and diagnosis for patients and physicians outside medical facilities. The new patents enable HeartBeam to expand the reach and impact of its groundbreaking 3D ECG technology, contributing to the transformation of cardiac care. For more details, visit https://ibn.fm/RgRun.
HeartBeam is developing the first cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed for use in portable devices, allowing actionable heart intelligence to be delivered wherever the patient is. Physicians can identify cardiac health trends and acute conditions, directing patients to appropriate care outside medical facilities, thereby redefining cardiac health management.
The company's growing IP portfolio, which includes 13 U.S. and 4 international issued patents related to technology enablement, underscores its commitment to innovation in the medical technology sector. This advancement is crucial as it addresses the increasing need for remote healthcare solutions, potentially improving accessibility and timeliness of cardiac diagnostics for patients worldwide.
For further information about HeartBeam, visit https://www.HeartBeam.com. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
